Sanofi–Translate Bio COVID-19 vaccine

Sanofi–Translate Bio COVID-19 vaccine
Vaccine description
TargetSARS-CoV-2
Vaccine typemRNA
Clinical data
Other namesMRT5500, VAW00001
Routes of
administration
Intramuscular
Legal status
Legal status
Identifiers
CAS Number

The Sanofi–Translate Bio COVID-19 vaccine, also known as MRT5500 or VAW00001, was a COVID-19 vaccine candidate developed by Sanofi Pasteur and Translate Bio.[3][4] The development was stopped in September 2021.[5]

  1. ^ Abboud L (28 September 2021). "Sanofi stops development of Covid vaccine based on mRNA technology". Financial Times.
  2. ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
  3. ^ "Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate". Sanofi. 12 March 2021. Archived from the original on 9 October 2021. Retrieved 20 March 2021.
  4. ^ "Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older (VAW00001)". United States National Library of Medicine. Retrieved 20 March 2021.
  5. ^ "Sanofi drops plans for messenger RNA vaccine against virus". Associated Press. 28 September 2021. Archived from the original on 14 October 2021. Retrieved 7 October 2021.